A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy
C5 inhibitor
C5 inhibitor
陳彩雲
III
Eculizumab
Untreat or Eculizumab stop over 3 m or Ravulizumab stop over 6 m
Age: Phase: III
Unknown
李佳玲
4620